Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV003126918 | SCV003802725 | likely benign | Monogenic diabetes | 2023-01-12 | reviewed by expert panel | curation | The c.408G>A variant in the hepatocyte nuclear factor 4 alpha gene, HNF4A, is a synonymous (silent) variant at codon 136 (p.(Ala136=)) of NM_175914.5. This variant is not predicted by SpliceAI to impact splicing (SpliceAI scores less than the MDEP cutoff of 0.2) and is not highly conserved (phyloP100way score of -1.087, which is below the MDEP cutoff of 2.0) (BP4, BP7). The Popmax frequency of the c.408G>A variant in gnomAD v2.1.1 is 0.00002619, which falls between ClinGen MDEP-established cutoffs for PM2_Supporting and BS1; thus, neither criterion will be applied. In summary, c.408G>A meets the criteria to be classified as likely benign for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (specification version 1.0, approved 11/16/22): BP4, BP7. |
Athena Diagnostics | RCV000711957 | SCV000842368 | benign | not provided | 2017-12-30 | criteria provided, single submitter | clinical testing | |
Clinical Genomics, |
RCV003148848 | SCV003804630 | benign | Maturity onset diabetes mellitus in young | criteria provided, single submitter | research | Potent mutations in HNF4A are associated with poor insulin secretion in response to hyperglycemia. Associated with MODY1. Patients initially respond well to sulfonylureas but eventually become insulin dependent. However, more evidence is required to ascertain the role of this particular variant rs374298096 in MODY, yet. | |
Labcorp Genetics |
RCV000711957 | SCV004276483 | benign | not provided | 2023-06-15 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV000711957 | SCV005311835 | benign | not provided | criteria provided, single submitter | not provided |